annual EBITDA:
-$68.40M+$2.58M(+3.64%)Summary
- As of today (May 29, 2025), ABUS annual EBITDA is -$68.40 million, with the most recent change of +$2.58 million (+3.64%) on December 31, 2024.
- During the last 3 years, ABUS annual EBITDA has risen by +$3.23 million (+4.51%).
- ABUS annual EBITDA is now -300.11% below its all-time high of $34.18 million, reached on December 31, 2012.
Performance
ABUS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$24.17M-$12.00M(-98.60%)Summary
- As of today (May 29, 2025), ABUS quarterly EBITDA is -$24.17 million, with the most recent change of -$12.00 million (-98.60%) on March 31, 2025.
- Over the past year, ABUS quarterly EBITDA has dropped by -$6.69 million (-38.29%).
- ABUS quarterly EBITDA is now -159.54% below its all-time high of $40.59 million, reached on December 31, 2012.
Performance
ABUS quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$75.09M-$6.69M(-9.78%)Summary
- As of today (May 29, 2025), ABUS TTM EBITDA is -$75.09 million, with the most recent change of -$6.69 million (-9.78%) on March 31, 2025.
- Over the past year, ABUS TTM EBITDA has dropped by -$2.44 million (-3.36%).
- ABUS TTM EBITDA is now -318.98% below its all-time high of $34.29 million, reached on December 31, 2012.
Performance
ABUS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ABUS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3.6% | -38.3% | -3.4% |
| 3 y3 years | +4.5% | -131.9% | -12.3% |
| 5 y5 years | +57.8% | -96.2% | +50.5% |
ABUS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -10.6% | +4.5% | -131.9% | at low | -23.4% | +0.5% |
| 5 y | 5-year | -18.4% | +57.8% | -131.9% | at low | -30.0% | +50.5% |
| alltime | all time | -300.1% | +86.0% | -159.5% | +90.7% | -319.0% | +84.7% |
ABUS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$24.17M(+98.6%) | -$75.09M(+9.8%) |
| Dec 2024 | -$68.40M(-3.6%) | -$12.17M(-37.1%) | -$68.40M(-9.0%) |
| Sep 2024 | - | -$19.35M(-0.3%) | -$75.14M(-0.4%) |
| Jun 2024 | - | -$19.41M(+11.0%) | -$75.48M(+3.9%) |
| Mar 2024 | - | -$17.48M(-7.6%) | -$72.66M(+2.4%) |
| Dec 2023 | -$70.99M(+14.8%) | -$18.91M(-4.0%) | -$70.99M(-3.3%) |
| Sep 2023 | - | -$19.69M(+18.7%) | -$73.39M(+4.1%) |
| Jun 2023 | - | -$16.58M(+4.9%) | -$70.50M(+4.8%) |
| Mar 2023 | - | -$15.81M(-25.8%) | -$67.25M(+8.7%) |
| Dec 2022 | -$61.86M(-13.6%) | -$21.32M(+26.9%) | -$61.86M(+1.6%) |
| Sep 2022 | - | -$16.80M(+26.0%) | -$60.88M(-1.9%) |
| Jun 2022 | - | -$13.33M(+27.9%) | -$62.03M(-7.3%) |
| Mar 2022 | - | -$10.42M(-48.8%) | -$66.89M(-6.6%) |
| Dec 2021 | -$71.64M(+24.0%) | -$20.33M(+13.3%) | -$71.64M(+6.8%) |
| Sep 2021 | - | -$17.95M(-1.3%) | -$67.06M(+1.1%) |
| Jun 2021 | - | -$18.19M(+19.9%) | -$66.30M(+9.4%) |
| Mar 2021 | - | -$15.17M(-3.8%) | -$60.60M(+4.9%) |
| Dec 2020 | -$57.76M(-64.4%) | -$15.76M(-8.3%) | -$57.76M(-11.4%) |
| Sep 2020 | - | -$17.19M(+37.7%) | -$65.15M(-54.0%) |
| Jun 2020 | - | -$12.49M(+1.4%) | -$141.51M(-6.8%) |
| Mar 2020 | - | -$12.32M(-46.8%) | -$151.83M(-6.4%) |
| Dec 2019 | -$162.24M(+175.3%) | -$23.15M(-75.3%) | -$162.24M(+3.5%) |
| Sep 2019 | - | -$93.55M(+310.2%) | -$156.71M(+71.4%) |
| Jun 2019 | - | -$22.81M(+0.3%) | -$91.42M(+40.8%) |
| Mar 2019 | - | -$22.73M(+29.0%) | -$64.94M(+10.2%) |
| Dec 2018 | -$58.94M(-44.6%) | -$17.62M(-37.6%) | -$58.94M(-41.6%) |
| Sep 2018 | - | -$28.26M(-870.2%) | -$100.87M(+20.7%) |
| Jun 2018 | - | $3.67M(-121.9%) | -$83.54M(-20.4%) |
| Mar 2018 | - | -$16.72M(-71.9%) | -$104.92M(-1.4%) |
| Dec 2017 | -$106.44M(-78.2%) | -$59.56M(+444.8%) | -$106.44M(-65.1%) |
| Sep 2017 | - | -$10.93M(-38.3%) | -$305.39M(-2.7%) |
| Jun 2017 | - | -$17.71M(-3.0%) | -$313.76M(-36.1%) |
| Mar 2017 | - | -$18.25M(-92.9%) | -$490.67M(+0.5%) |
| Dec 2016 | -$488.07M(+523.2%) | -$258.50M(+1239.1%) | -$488.07M(+83.9%) |
| Sep 2016 | - | -$19.30M(-90.1%) | -$265.39M(-0.3%) |
| Jun 2016 | - | -$194.61M(+1143.0%) | -$266.08M(+211.6%) |
| Mar 2016 | - | -$15.66M(-56.3%) | -$85.38M(+9.0%) |
| Dec 2015 | -$78.31M | -$35.82M(+79.1%) | -$78.31M(+47.4%) |
| Sep 2015 | - | -$20.00M(+43.7%) | -$53.13M(+33.3%) |
| Jun 2015 | - | -$13.91M(+61.9%) | -$39.85M(+13.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | -$8.59M(-19.2%) | -$35.21M(+8.5%) |
| Dec 2014 | -$32.44M(+181.2%) | -$10.63M(+58.5%) | -$32.44M(+34.6%) |
| Sep 2014 | - | -$6.71M(-27.6%) | -$24.10M(+15.4%) |
| Jun 2014 | - | -$9.27M(+59.2%) | -$20.89M(+43.7%) |
| Mar 2014 | - | -$5.82M(+154.4%) | -$14.54M(+26.0%) |
| Dec 2013 | -$11.54M(-133.8%) | -$2.29M(-34.7%) | -$11.54M(-136.8%) |
| Sep 2013 | - | -$3.50M(+20.0%) | $31.34M(-5.8%) |
| Jun 2013 | - | -$2.92M(+3.2%) | $33.26M(-1.8%) |
| Mar 2013 | - | -$2.83M(-107.0%) | $33.86M(-1.2%) |
| Dec 2012 | $34.18M(-452.2%) | $40.59M(-2663.5%) | $34.29M(-497.2%) |
| Sep 2012 | - | -$1.58M(-31.7%) | -$8.63M(+2.5%) |
| Jun 2012 | - | -$2.32M(-3.5%) | -$8.43M(-12.3%) |
| Mar 2012 | - | -$2.40M(+2.8%) | -$9.60M(-5.1%) |
| Dec 2011 | -$9.71M(+74.6%) | -$2.33M(+69.6%) | -$10.12M(+164.3%) |
| Sep 2011 | - | -$1.38M(-60.6%) | -$3.83M(-17.0%) |
| Jun 2011 | - | -$3.49M(+19.7%) | -$4.62M(+1.9%) |
| Mar 2011 | - | -$2.92M(-173.7%) | -$4.53M(-17.9%) |
| Dec 2010 | -$5.56M(-22.3%) | $3.96M(-283.2%) | -$5.52M(-51.9%) |
| Sep 2010 | - | -$2.16M(-36.6%) | -$11.47M(+2.5%) |
| Jun 2010 | - | -$3.41M(-12.8%) | -$11.19M(+21.2%) |
| Mar 2010 | - | -$3.91M(+96.7%) | -$9.23M(+38.3%) |
| Dec 2009 | -$7.15M(-1.0%) | -$1.99M(+5.8%) | -$6.67M(+53.7%) |
| Sep 2009 | - | -$1.88M(+29.6%) | -$4.34M(-7.0%) |
| Jun 2009 | - | -$1.45M(+7.0%) | -$4.67M(-42.2%) |
| Mar 2009 | - | -$1.35M(-494.6%) | -$8.08M(+8.7%) |
| Dec 2008 | -$7.23M(-336.9%) | $343.20K(-115.6%) | -$7.43M(-0.8%) |
| Sep 2008 | - | -$2.21M(-54.6%) | -$7.49M(+112.0%) |
| Jun 2008 | - | -$4.86M(+586.1%) | -$3.53M(-319.2%) |
| Mar 2008 | - | -$708.50K(-350.1%) | $1.61M(-30.5%) |
| Dec 2007 | $3.05M(-85.0%) | $283.30K(-83.8%) | $2.32M(+13.9%) |
| Sep 2007 | - | $1.75M(+513.4%) | $2.04M(+613.4%) |
| Jun 2007 | - | $285.60K | $285.60K |
| Dec 2006 | $20.41M(+1457.9%) | - | - |
| Dec 2005 | $1.31M(-107.3%) | - | - |
| Dec 2004 | -$17.90M(-35.5%) | - | - |
| Dec 2003 | -$27.76M(+51.2%) | - | - |
| Dec 2002 | -$18.36M(+46.0%) | - | - |
| Dec 2001 | -$12.57M(+33.6%) | - | - |
| Dec 2000 | -$9.41M(+37.0%) | - | - |
| Dec 1999 | -$6.87M(-11.5%) | - | - |
| Dec 1998 | -$7.76M | - | - |
FAQ
- What is Arbutus Biopharma annual EBITDA?
- What is the all time high annual EBITDA for Arbutus Biopharma?
- What is Arbutus Biopharma annual EBITDA year-on-year change?
- What is Arbutus Biopharma quarterly EBITDA?
- What is the all time high quarterly EBITDA for Arbutus Biopharma?
- What is Arbutus Biopharma quarterly EBITDA year-on-year change?
- What is Arbutus Biopharma TTM EBITDA?
- What is the all time high TTM EBITDA for Arbutus Biopharma?
- What is Arbutus Biopharma TTM EBITDA year-on-year change?
What is Arbutus Biopharma annual EBITDA?
The current annual EBITDA of ABUS is -$68.40M
What is the all time high annual EBITDA for Arbutus Biopharma?
Arbutus Biopharma all-time high annual EBITDA is $34.18M
What is Arbutus Biopharma annual EBITDA year-on-year change?
Over the past year, ABUS annual EBITDA has changed by +$2.58M (+3.64%)
What is Arbutus Biopharma quarterly EBITDA?
The current quarterly EBITDA of ABUS is -$24.17M
What is the all time high quarterly EBITDA for Arbutus Biopharma?
Arbutus Biopharma all-time high quarterly EBITDA is $40.59M
What is Arbutus Biopharma quarterly EBITDA year-on-year change?
Over the past year, ABUS quarterly EBITDA has changed by -$6.69M (-38.29%)
What is Arbutus Biopharma TTM EBITDA?
The current TTM EBITDA of ABUS is -$75.09M
What is the all time high TTM EBITDA for Arbutus Biopharma?
Arbutus Biopharma all-time high TTM EBITDA is $34.29M
What is Arbutus Biopharma TTM EBITDA year-on-year change?
Over the past year, ABUS TTM EBITDA has changed by -$2.44M (-3.36%)